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Transcription of the Streptococcus pyogenes Hyaluronic Acid Capsule
Biosynthesis Operon Is Regulated by Previously Unknown Upstream
Elements
Marina Falaleeva,a Oliwia W. Zurek,b Robert L. Watkins,b Robert W. Reed,a Hadeel Ali,a Paul Sumby,c Jovanka M. Voyich,b
Natalia Korotkovaa
Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USAa; Department of Microbiology and Immunology, Montana State
University, Bozeman, Montana, USAb; Department of Molecular Microbiology & Immunology, University of Nevada, Reno, Nevada, USAc
The important human pathogen Streptococcus pyogenes (group A Streptococcus [GAS]) produces a hyaluronic acid (HA) cap-
sule that plays critical roles in immune evasion. Previous studies showed that the hasABC operon encoding the capsule biosyn-
thesis enzymes is under the control of a single promoter, P1, which is negatively regulated by the two-component regulatory sys-
tem CovR/S. In this work, we characterize the sequence upstream of P1 and identify a novel regulatory region controlling
transcription of the capsule biosynthesis operon in theM1 serotype strainMGAS2221. This region consists of a promoter, P2,
which initiates transcription of a novel small RNA, HasS, an intrinsic transcriptional terminator that inefficiently terminates
HasS, permitting read-through transcription of hasABC, and a putative promoter which lies upstream of P2. Electrophoretic
mobility shift assays, quantitative reverse transcription-PCR, and transcriptional reporter data identified CovR as a negative
regulator of P2. We found that the P1 and P2 promoters are completely repressed by CovR, and capsule expression is regulated
by the putative promoter upstream of P2. Deletion of hasS or of the terminator eliminates CovR-binding sequences, relieving
repression and increasing read-through, hasA transcription, and capsule production. Sequence analysis of 44 GAS genomes re-
vealed a high level of polymorphism in the HasS sequence region. Most of the HasS variations were located in the terminator
sequences, suggesting that this region is under strong selective pressure. We discovered that the terminator deletion mutant is
highly resistant to neutrophil-mediated killing and is significantly more virulent in a mouse model of GAS invasive disease than
the wild-type strain. Together, these results are consistent with the naturally occurring mutations in this regionmodulating GAS
virulence.
Streptococcus pyogenes (group A streptococcus [GAS]) is a com-mon human pathogen that causes a variety of diseases, includ-
ing minor skin and throat infections, such as impetigo and
pharyngitis, and life-threatening invasive infections, such as strep-
tococcal toxic shock syndrome and necrotizing fasciitis. One of
the most important virulence factors that aid GAS in evasion of
the host immune system is the hyaluronic acid (HA) capsule.
Highly encapsulated GAS strains are associated with both severe
invasive infections and outbreaks of acute rheumatic fever (1). HA
capsule is a high-molecular-mass linear polymer consisting of
glucuronic acid and N-acetylglucosamine repeating units. As the
structure of GAS capsular HA is identical to HA produced by
mammalian tissues, this reduces the ability of the host immune
system to detect and kill infecting GAS cells. Indeed, GAS capsule
mutant strains have increased sensitivity to neutrophil-mediated
killing and reduced virulence in murine models of GAS infection
(2–6). The HA capsule not only enhances GAS immune evasion
through molecular mimicry but also promotes GAS survival
within neutrophil extracellular traps through the inhibition of the
human antimicrobial peptide cathelicidin (7). Furthermore, in
addition to its role in circumvention of the host immune response,
the HA capsule also enhances GAS virulence by mediating adher-
ence to CD44 expressed on the surface of human keratinocytes,
thus promoting GAS colonization (8, 9).
The enzymes involved in HA capsule biosynthesis are encoded
by the hasABC operon, which is present in all GAS serotypes thus
far tested, except M4 and M22 (10). HA capsule production re-
quires only the first gene of the operon, hasA, encoding hyaluro-
nate synthase (11). The enzyme forms an HA polymer from UDP-
activated sugar precursors. The operon also encodes two enzymes
involved in biosynthesis of the activated sugars, UDP-glucose de-
hydrogenase (encoded by hasB) and UDP-glucose pyrophosphor-
ylase (encoded by hasC) (12, 13). It has been shown that expres-
sion of the operon is under the control of a single promoter, P1,
located upstream of hasA (14). Transcription of the hasABC
operon is negatively regulated by the CovR/S two-component sig-
nal transduction system (also known as CsrR/S), which consists of
the CovS sensor kinase and the CovR response regulator (15–19).
It has been found that CovR recognizes and binds AT-rich DNA
regions surrounding the 10 and 35 elements of the P1 pro-
moter (15, 19, 20). Five short sites with consensus ATTARA have
been proposed to act as CovR-binding motifs (19).
The CovR/S system is a global GAS regulator responsible for
modulating the transcription of up to 10 to 15% of the genes in the
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genome, including important virulence determinants of GAS (21,
22). Spontaneous mutations in the covRS genes arise in vivo dur-
ing infection, resulting in capsule overproduction and hyperviru-
lence of GAS (22–24). Interestingly, some GAS isolates with a
functioning CovR/S system also produce a large capsule, raising
the possibility that additional layers of regulation of capsule ex-
pression exist (25).
In this study, we found a novel regulatory region upstream of
P1 which controls transcription of the capsule operon. We dem-
onstrated that deletion of this region has a positive effect on the
has operon transcription. This novel region consists of two pro-
moters and a transcriptional terminator that permits read-
through transcription of hasABC. We showed that the CovR/S
regulatory system negatively regulates P1 and one of the promot-
ers, P2, upstream of P1. Moreover, our mouse studies with the
terminator mutant indicate that this regulatory region signifi-
cantly contributes to GAS virulence. Finally, we found that this
region from multiple GAS strains displays a high level of sequence
variation in the P2 promoter and the terminator sequences. Given
the importance of this region in the regulation of capsule produc-
tion, this observation suggests that the mutations might alter
strain virulence.
MATERIALS AND METHODS
Bacterial strains and growth conditions. All plasmids, strains, and prim-
ers used in this study are listed in Tables S1, S2, and S3 in the supplemental
material. S. pyogenes MGAS2221 and SF370, M1 serotype strains (26, 27),
and the 2221covR mutant, the CovR deletion mutant of MGAS2221
(28), were used for most experiments and strain construction. The strains
used for capsule assay are listed in Table S1 in the supplemental material.
GAS cultures were grown in Todd-Hewitt broth supplemented with 0.2%
yeast extract (THY) or on THY agar plates. GAS strains were cultured
without aeration at 37°C. Escherichia coli strains were grown in Luria-
Bertani (LB) medium or on LB agar plates at 37°C. When required, anti-
biotics were included at the following concentrations: ampicillin at 100g
ml1 for E. coli, chloramphenicol at 10 g ml1 for E. coli and 5 g ml1
for GAS, and spectinomycin at 200 g ml1 for E. coli and 100 g ml1
for GAS.
DNA techniques. Plasmid DNA was isolated from E. coli by commer-
cial kits (Qiagen) according to the manufacturer’s instructions and used
to transform E. coli and GAS strains. Plasmids were transformed into GAS
by electroporation as described previously (29). Chromosomal DNA was
purified from GAS as described previously (30). To construct single-base
substitutions or deletion mutations, we used the QuikChange II XL site-
directed mutagenesis kit (Stratagene) according to the manufacturer’s
protocol. Constructs containing mutations were identified by sequence
analysis. Primers for site-directed mutagenesis are listed in Table S3 in the
supplemental material. All constructs were confirmed by sequencing
analysis (Eurofins MWG Operon).
Plasmid and strain construction. (i) Construction of isogenic
mutant strains. For construction of the mutants (2221P2hasS,
222163T, 222142T, 2221P2, 2221P1, 2221P2P1, 2221
covR42T, 2221covRP2hasS, 2221covRP1, 2221covRP2P1,
2221covR42TP1, and SF37063T mutants), either MGAS2221 or
SF370 chromosomal DNA was used as the templates for amplification of
a 1.4-kbp PCR product. The primer pair hasR-BamHI-f and hasR-XhoI-r
(see Table S2 in the supplemental material) was used to amplify a DNA
region flanking either side of the hasA upstream region. The PCR product
was digested with BamHI and XhoI and ligated into the BglII/XhoI-di-
gested pBBL740 plasmid (see Table S1 in the supplemental material). The
integrational plasmid pBBL740 does not have a replication origin that is
functional in GAS, so the plasmid can be maintained only by integrating
into the GAS chromosome through homologous recombination. To cre-
ate deletions in the hasA upstream sequence region, the resultant plasmid
pBBL740hasS was employed for site-directed mutagenesis using the
primer pair listed in Table S3 in the supplemental material. The resulting
plasmids were transformed into the MGAS2221, 2221covR, and SF370
strains, and chloramphenicol-resistant colonies were selected on THY
agar plates. Five randomly selected colonies that had the first crossover
and wild-type (WT) capsule concentration were grown in liquid THY
without chloramphenicol for5 serial passages. Several potential double-
crossover mutants were selected as previously described (31). The dele-
tion in each mutant was confirmed by sequencing a PCR fragment, and
the phenotypes of several mutant colonies were examined.
(ii) Reporter plasmids for luciferase expression. For construction of
transcriptional fusions of the P2 promoter with the firefly luciferase gene
(luc), we employed the pKSM720 plasmid, which carries a promoterless
luc with its ribosome-binding site (RBS) (32). To construct P2::luc fusion,
MGAS2221 chromosomal DNA and the primer pair P2-BglII-f and P2-
XhoI-r (see Table S2 in the supplemental material) were used to amplify a
141-bp PCR product. To construct a fusion of luc with the DNA fragment
carrying P2, hasS, and the terminator (P2T::luc fusion), the primer pair
P2-BglII-f and term-XhoI-r (see Table S2) was used to amplify a 184-bp
PCR product from MGAS2221 DNA. The PCR products were then cloned
into pKSM720 plasmid. The plasmids were designated pKSM720P2 and
pKSM720P2T, respectively (see Table S1). The resulting plasmids were
transformed into the MGAS2221 and 2221covR strains.
(iii) Plasmid for GAS expression of HasS. For expression of HasS, a
DNA fragment containing hasS with the P2 promoter region was ampli-
fied from MGAS2221 chromosomal DNA using primer pair hasS-f and
hasS-r (see Table S2 in the supplemental material). The PCR product was
then cloned into BglII/BamHI-digested pKSM720. The resultant plasmid,
pKSMhasS, was transformed into MGAS2221 by electroporation, and
transformants were selected on agar plates containing spectinomycin.
(iv) Plasmids for E. coli expression of covR. For construction of a
CovR expression plasmid, the primer pair covR-NcoI-f and covR-XhoI-r
(see Table S2 in the supplemental material) was employed to amplify the
covR gene from MGAS2221 chromosomal DNA. The PCR product was
digested with NcoI and XhoI and ligated into NcoI/XbaI-digested
pET21d. The resulting plasmid, pETCovR, contains covR fused at the C
terminus with the sequence encoding a His tag. To mimic the phosphor-
ylated state of CovR, the gene was mutated at aspartate 53 to glutamate
(D53E mutation). The resultant pETCovRD53E plasmid was transferred
into competent E. coli Rosetta(DE3) (Novagen) using the manufacturer’s
protocol.
Purification of the CovRD53Emutant.The CovR D53E mutant pro-
tein was expressed in E. coli Rosetta(DE3) harboring the pETCovRD53E
plasmid. The protein was purified by Ni-nitrilotriacetic acid chromatog-
raphy followed by size exclusion chromatography on Superdex 200. Based
on the results obtained by analytical size exclusion chromatography, the
CovR mutant protein forms stable dimers. Dimerization of CovR is con-
sidered necessary for transcription regulation of the has operon (33).
RNA extraction. Total RNA was isolated from GAS grown to the mid-
exponential phase (optical density at 600 nm [OD600] of 0.6) using the
miRNeasy kit (Qiagen) according to the manufacturer’s instructions.
Contaminating genomic DNA was removed from eluted RNA samples
with Turbo DNase (Applied Biosystems), with DNA removal being veri-
fied by PCR.
RT-PCR analysis. RNA isolated from MGAS2221 was used in two
cDNA synthesis reactions, where one of the reaction mixtures did not
have any reverse transcriptase added (RT; to be used as a control against
contaminating genomic DNA). Isolated genomic DNA (gDNA) from
MGAS2221 and the RT and RT cDNA synthesis reactions were each
used as the template in PCRs with primers R/F1, R/F2, R/F3, and R/F4 (see
Table S2 in the supplemental material; see also Fig. 6A). Reaction products
were separated by electrophoresis, and the gel was imaged.
qRT-PCR.To determine relative mRNA abundance of hasS, hasA, and
the read-through product, we employed quantitative RT-PCR (qRT-
Falaleeva et al.
5294 iai.asm.org Infection and Immunity
 o
n
 D
ecem
ber 7, 2015 by UNIV O
F KENTUCKY
http://iai.asm
.org/
D
ow
nloaded from
 
PCR). The housekeeping gene plr was used as an internal standard for
normalization. To obtain cDNA for qRT-PCR, 4 g of total RNA was
reverse transcribed with SuperScript III RT (Invitrogen) using both re-
verse target-specific primer and reverse plr-specific primer. qRT-PCRs
were performed using an Mx3005P qPCR system (Agilent Technologies)
under standard reaction conditions. The reaction mixture contained
Power SYBR green PCR master mix (Applied Biosystems), cDNA, and
both gene-specific primers (see Table S2 in the supplemental material).
hasSwas analyzed using the hasSRT-f and hasSRT-r primer pair. hasAwas
analyzed using the hasART-f and hasART-r primer pair. The read-
through product was analyzed using the rtqRT-f and rtqRT-r primer pair.
plr was analyzed in each cDNA reaction using the plr-f and plr-r primer
pair. No-template and no-RT controls were included for each primer set
and template. The expression levels of each target under each condition
tested were normalized to the levels of plr transcript. Data are reported as
the mean values of fold change for hasS, hasA, and the read-through
mRNA levels in the mutants relative to those of the MGAS2221 WT strain.
Each experiment was performed in triplicate, and mean values standard
deviations (SDs) are shown. Error bars represent standard deviations
from three independent experiments.
Expression and purification of core RNA polymerase from GAS.
Core RNA polymerase was purified from the GAS JRS4-PolHis strain (34)
as previously described (35).
Expression and purification of A of GAS from E. coli. GAS A was
purified from E. coli Rosetta(DE3) carrying pEU7534 plasmid as previ-
ously described (36).
In vitro transcription and isolation of RNAproducts. DNA template
employed for the HasS transcriptional reaction was PCR amplified from
MGAS2221 genomic DNA using the pair of primers 1 and RNA-has-r1
(see Table S2 in the supplemental material). DNA templates employed for
hasA transcription were PCR amplified from MGAS2221 and 2221P1
genomic DNA using the P1-f and P1-r primer pair. In vitro transcription
reaction was performed as previously described (37) with modifications.
Briefly, purified GAS core RNA polymerase and A, transcriptional buf-
fer, SUPERase In RNase inhibitor (Ambion), and DNA template were
mixed and incubated at room temperature for 10 min. The reaction was
started by adding a mixture of ribonucleotides containing [32P]UTP
(PerkinElmer) and incubated at 37°C. For time course in vitro transcrip-
tion, the sample aliquots were withdrawn at various time points. The
reaction was terminated by adding ethanol for RNA precipitation. RNA
products were resuspended in formamide loading dye (Thermo Scien-
tific) and run on a 10% denaturing urea polyacrylamide gel. The gel was
imaged using a Typhoon imaging system.
To determine 5= and 3= ends of RNA products, the in vitro transcrip-
tion reaction mixture was incubated for 30 min and terminated by adding
2 units DNase I (Invitrogen) followed by incubation at 37°C for 15 min.
DNase I was inactivated by adding EDTA to a final concentration of 5
mM. Products were ethanol precipitated, resuspended in formamide
loading dye, and run on a 10% denaturing urea polyacrylamide gel. The
radioactive bands were cut from a gel and incubated with probe elution
buffer (RPA III kit; Invitrogen) overnight to extract RNA. RNA products
were ethanol precipitated and used to identify 5= and 3= ends as described
below.
RACE. 5= rapid amplification of cDNA ends (5=-RACE) assays were
carried out using the FirstChoice RLM-RACE kit (Invitrogen) as per the
manufacturer’s instructions with minor modifications. First, the dephos-
phorylation step was omitted from the protocol. Second, the products
obtained by in vitro transcription were reverse transcribed using random
decamers. The total cellular RNA isolated from MGAS2221 was reverse
transcribed using the HasS-specific reverse primer hasSRT-r (see Table S2
in the supplemental material). 3=-RACE assays were carried out essentially
as was described previously (38). PCR products were gel eluted and cloned
in pCR2.1-TOPO using the TOPO TA cloning kit (Invitrogen). Eight to
10 clones were selected and sequenced to determine 5= and 3= ends of
RNAs.
RPA. RNase protection assay (RPA) was done by use of the RPA III
RNase protection assay kit (Invitrogen). In brief, total RNA was isolated
from GAS strains grown to the mid-exponential phase (OD600 of 0.6). An
antisense RNA probe was prepared by PCR amplification using primer
pair RPA-f and RPA-r. A 63-bp PCR product was subcloned into pCR2.1-
TOPO (Invitrogen) so that the antisense RNA probe used in the RNase
protection assay would be synthesized from the T7 promoter. Radiola-
beled probe was prepared by transcription of SphI-digested plasmid by
using a MAXIscript T7 kit (Invitrogen) and [-32P]UTP (PerkinElmer).
The probe was hybridized to 50 g of total RNA overnight at 42°C. Pro-
tected hybrids were resolved on a 10% denaturing polyacrylamide se-
quencing gel.
Luciferase assay.The luciferase assay was performed using a luciferase
assay system (Promega). For assessment of luciferase reporter activity, the
bacteria were grown in THY broth under spectinomycin selection to an
OD600 of 0.6. Two-microliter aliquots of cell suspensions were pelleted
and resuspended in various amounts of 1	 lysis buffer to normalize to the
optical density of the samples. The luciferase assay was read using a Spec-
traMax M5 multimode microplate reader (Molecular Devices). All exper-
iments were performed in triplicate. For assessment of reporter activity
during GAS growth, 2-ml aliquots of cell suspensions were withdrawn at
various time points, and the OD600 was measured. The bacterial suspen-
sion was processed as described above.
Gel mobility shift assay. The P2 promoter probe was generated by
PCR amplification of MGAS2221 genomic DNA using the pair of primers
2 and RNA-has-r1 (see Table S2 in the supplemental material). The P2
promoter probe with a deleted HasS region was generated similarly by
PCR amplification of 222142T genomic DNA. mga promoter probe was
generated by PCR amplification of MGAS2221 genomic DNA using the
mga-f and mga-r primer pair. PCR fragments were end labeled with
[
32P]ATP using T4 polynucleotide kinase (New England BioLabs). Elec-
trophoretic mobility shift assay (EMSA) was performed essentially as de-
scribed in the gel shift assay system (Promega). Briefly, a labeled promoter
probe DNA (1.7 M) was incubated with increasing concentrations of
CovR (0.4 to 16.3 M). Nonradioactive P2 (85 M) and mga (100 M)
promoter DNA fragments were used in the reaction as specific and
nonspecific competitors, respectively. As a nonspecific competitor,
poly(dI-dC) · poly(dI-dC) (10 g/ml) was used in the reaction. The
reaction mixtures were run on a 10% native polyacrylamide gel. The
gel was imaged using a Typhoon imaging system.
Hyaluronic acid capsule assay. The amounts of hyaluronic acid cap-
sule were determined in GAS cultured to mid-exponential phase of
growth (OD600 of 0.5) as previously described (39) with minor modifica-
tion. Bacteria from a 2-ml exponential-phase culture were washed twice
with water and resuspended in 0.5 ml water. Capsule was released by
shaking with 1 ml of chloroform for 1 h. Tubes were then recentrifuged at
14,000 	 g for 10 min, and 0.2 ml of aqueous layer was removed and
combined with 0.6 ml of a solution containing 20 mg of Stains-All (Sigma)
and 60 l acetic acid in 100 ml of 50% formamide. The hyaluronic acid
content was determined by measuring absorbance at 640 nm. Absorbance
values were compared with a standard curve generated with known con-
centrations of hyaluronic acid.
GAS survival in human blood. Heparinized venous blood samples
were collected from healthy donors in accordance with protocols ap-
proved by the Institutional Review Boards for Human Subjects at Mon-
tana State University. Bacteria were harvested at the mid-exponential
phase of growth. One milliliter of heparinized human blood was inocu-
lated with 1	 105 GAS at 37°C for 1 h and 3 h with shaking. The survival
of bacteria was determined by plating bacteria on THY agar plates and
comparing CFU of each sample.
Polymorphonuclear leukocyte (PMN) isolation and PMN bacteri-
cidal assay. Neutrophils were isolated under endotoxin-free conditions
(25.0 pg/ml) as described previously (40–42).
The ability of GAS to survive phagocytosis by neutrophils was assessed
using synchronized phagocytosis as described previously (40) with the
Regulation of Capsule Operon Transcription in GAS
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following modification: experiments were performed in 96-well plates.
The percent survival of bacteria after incubation in the presence of PMNs
was calculated using the formula (CFUn/CFU0)	 100, where CFU0 is the
number of viable bacteria incubated with Hanks’ balanced salt solution
(HBSS) and CFUn is the number of surviving bacteria after incubation
with PMNs.
Mouse infections. All studies conformed to NIH guidelines and were
approved by the Animal Care and Use Committee at Montana State Uni-
versity. Female BALB/c mice (Charles River Laboratories) were used for
all mouse infection studies. Mice were inoculated via intraperitoneal in-
jection with 100 l of sterile saline containing 1 	 108 GAS CFU. To
determine bacterial burdens, mice were sacrificed at 10 h postinfection
and the peritoneal cavity was washed with 10 ml of HBSS using an 18-
gauge needle and a 10-ml syringe. The washes were serially diluted in
distilled water (dH2O) and plated on THY agar plates. To determine GAS
burdens in tissues, hearts and kidneys were aseptically removed, washed
in dH2O, and homogenized in dH2O. The number of CFU in the organs
was quantified by plating serial dilutions of the homogenized material on
THY agar plates.
Bioinformatics tools.RNA secondary structures were predicted using
the mfold program (43) (http://mfold.rna.albany.edu/?qmfold). The
prediction with the highest folding free-energy value was utilized.
Statistical data analysis. All data sets were analyzed with GraphPad
Prism, version 5.0 (GraphPad Software, San Diego, CA). All mouse data
sets were analyzed with paired t tests on a log scale. Real-time PCR analysis
and capsule and luciferase assays were performed a minimum of three
times. Significant differences between two values were compared with a
paired Student t test. Values were considered significantly different when
P values were0.05.
RESULTS
Identification of a small RNA (sRNA) upstream of the hasABC
operon.Our interest in the hasABC locus was driven in part by the
importance of the HA capsule to GAS virulence and in part by the
observation that the intergenic region upstream of hasA and
downstream of M5005_Spy_1850 was 430 bp in size in M1 sero-
type strains. An intergenic region of 430 bp is unusual for GAS,
where the average size is less than 100 bp, possibly indicating the
existence of an uncharacterized gene or regulatory feature in this
region. mfold analysis for RNA secondary structure (43) of the
hasA upstream region in M1 serotype GAS shown in Fig. 1A pre-
dicted a potential stem-loop structure 25 bp long with a G of
10.17 kcal/mol at 25°C. The stem-loop structure is followed by a
string of U’s and is predicted to act as a rho-independent termi-
nator during transcription. This putative terminator is located
approximately 50 bp upstream of the previously described P1 pro-
moter (Fig. 1A) and does not overlap CovR-binding sites previ-
ously predicted upstream of the P1 promoter (19).
To test whether the terminator is associated with a tran-
script and identify the transcriptional start of the RNA, we
employed 5= rapid amplification of cDNA ends (5=-RACE)
analysis. The transcriptional start was found upstream of the
putative terminator in MGAS2221 (M1 serotype GAS strain).
The 5= terminus of the 5=-RACE product mapped to an ade-
nine residue located 193 bp upstream of the hasA translation
start codon (Fig. 1A). This site is preceded by a putative pro-
moter, P2, which consists of a near-consensus 10 hexamer
(5=-TAAAAT-3=) preceded by a 10 extension (5=-TTTG-3=)
typical of A-type promoters from Gram-positive bacteria (44–
47). No consensus 35 sequence was present at a suitable dis-
tance from the 10 promoter sequence. It is noteworthy that
the promoters with extended10 sequence can function in the
absence of a35 site (44, 46). In addition to A, GAS contains
an alternative sigma factor, X homolog, which recognizes a
sequence called the “cin-box” (34). Examination of the hasA
upstream sequence did not revealed any putative “cin-box”
promoters, suggesting that X does not control transcription in
this region.
To examine the activity of the P2 promoter and investigate
whether the predicted terminator is able to terminate efficiently,
we assayed the transcription of the hasA upstream region in vitro
with a GAS-specific transcription system which contains GAS core
RNA polymerase and GAS housekeeping sigma factor A. Previ-
ously, this system has been successfully employed to study tran-
scription of GAS genes (33, 35, 36, 48, 49). RNA polymerase was
purified from the GAS JRS4-PolHis strain, and recombinant GAS
A was purified from E. coli Rosetta(DE3) carrying pEU7534 plas-
mid (36). As a template for the in vitro reaction, we used a 240-bp
PCR fragment carrying the P2 promoter, the terminator, and 82
bp downstream of the P2 promoter. We detected two major tran-
scriptional products 58 and 73 nucleotides (nt) long (Fig. 1B). The
transcriptional profiles were consistent with the products initiated
from the P2 promoter. 5=-RACE analysis of the products validated
our previously determined transcriptional start. 3=-RACE analysis
revealed that the 58-nt product ends at the terminator and the
73-nt product is the result of read-through at the terminator.
In order to examine whether this region has additional pro-
moters between P1 and P2, we analyzed in vitro transcription us-
ing a 300-bp PCR fragment carrying the P1 promoter and 110 bp
upstream of the35 box of P1 (see Fig. S1A in the supplemental
material). We detected a 150-bp runoff transcript consistent with
the product being initiated from the P1 promoter (see Fig. S1B).
No transcript was observed when the10 element of the P1 pro-
moter was mutated from TAGAAT to TCTAGA.
Taken together, our data indicate that the analyzed hasA up-
stream region encodes at least one additional promoter that initi-
ates transcription of a small RNA as well as a larger RNA that
includes the downstream hasA gene. We designated the sRNA
HasS. Moreover, we further confirmed the existence of transcripts
originating upstream of the P1 promoter region by RNase protec-
tion assay (RPA) using a radiolabeled antisense 58-nt RNA probe
to HasS. The probe was used for hybridization with RNA isolated
from three different strains: MGAS2221, a covR deletion mutant
strain (2221covR), and MGAS2221 carrying a plasmid with hasS
under the P2 promoter (2221/pKSMhasS). A weak signal corre-
sponding to a 58-nt protected fragment was detected in the
2221covR and 2221/pKSMhasS strains but not in the wild-type
(WT) strain (see Fig. S2 in the supplemental material). These data
indicate that HasS is a low-abundance sRNA which is negatively
regulated by CovR.
Deletionof theHasS region affects capsule operon transcrip-
tion. To facilitate investigation of what functions HasS and the
terminator have in GAS, we constructed four mutants in the
parental isolate MGAS2221: the 2221P2, 2221P2hasS,
222142T, and 222163T mutants (Fig. 2A). In the 2221P2
strain, we deleted the P2 promoter. In the 2221P2hasS strain,
we deleted the P2 promoter and the entire hasS sequence, includ-
ing the stem-loop terminator and the T-rich region located im-
mediately downstream. In the 222142T strain, we created a
42-nt deletion which included the HasS stem-loop terminator se-
quence and the T-rich region located immediately downstream.
In the 222163T strain, we created a 63-nt deletion which in-
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cluded the HasS stem-loop terminator sequence, the T-rich re-
gion, and 25 nt located immediately downstream. Since HasS is
transcribed adjacent to the hasABC operon, we hypothesized that
it regulates HA capsule production in GAS. To test this hypothesis,
HA capsule concentration was measured from GAS cultures
grown to the mid-exponential phase of growth. We found that the
2221P2, 2221P2hasS, 222142T, and 222163T mutants
had increased capsule expression relative to that of the WT strain
(Fig. 2B).
The 2221P2hasS and 222163T mutants demonstrated the
most significant increase in capsule expression, producing 3 and
3.7 times more capsule, respectively, than the WT strain (Fig. 2B).
To determine whether the elevated capsule amount resulted from
upregulation of the has operon at a transcriptional level, we exam-
ined the transcription of hasA in the WT and the 2221P2hasS
and 222163T mutants using quantitative RT-PCR (qRT-PCR)
analysis. The mutants produced 4.5 times more transcript than
the WT strain (Fig. 3A).
To investigate whether upregulated has transcription is the re-
sult of deletion of previously unrecognized CovR-binding sites
located in the HasS region, we constructed two mutants in the
CovR deletion mutant background: 2221covRP2hasS and
2221covR42T (Fig. 2A). We found that the mutations had no
effect on capsule production in this strain background. Taken
FIG 1 The hasA upstream region encodes P1 and P2 promoters and a terminator. (A) Nucleotide sequence of the hasA upstream region in the GAS M1 serotype.
35,10, and extended10 promoter regions of P1 and P2 and M5005_Spy_1850 are underlined. Bent arrows denote the transcriptional start sites of hasA and
hasS. The hasA transcriptional start site is according to the published results of primer extension analysis (63), and HasS was identified by 5=-RACE analysis. The
vertical arrow depicts the termination site of HasS identified by 3=-RACE analysis of the in vitro transcriptional product. Horizontal arrows indicate the location
of the primers, 1 and RNA-has-r1 (see Table S2 in the supplemental material), used for PCR amplification of a template employed for in vitro transcription of
HasS. Gray shaded boxes indicate the location of start codons. The previously reported putative CovR-binding sites (19) in the hasA upstream region (open
boxes) and putative CovR-binding sites in the P2 promoter and HasS regions (dotted boxes) are shown. Note that the fifth reported CovR-binding site lies within
the hasA coding region and is not shown. (B) Time course of in vitro RNA synthesis from a PCR product carrying the P2 promoter and the terminator sequences.
Shown is a 10% denaturing urea polyacrylamide gel containing in vitro transcribed RNA products using purified GAS RNA polymerase and A (36). Lane 1, 5
min; lane 2, 10 min; lane 3, 20 min; lane 4, 30 min; lane 5, 1 h. The RNA ladder is labeled in bases. * denotes an HasS read-through product.
Regulation of Capsule Operon Transcription in GAS
December 2014 Volume 82 Number 12 iai.asm.org 5297
 o
n
 D
ecem
ber 7, 2015 by UNIV O
F KENTUCKY
http://iai.asm
.org/
D
ow
nloaded from
 
together, our results indicate that the HasS region regulates the
transcription of the capsule biosynthesis operon, and this regula-
tion is most probably due to CovR binding.
CovR directly represses HasS transcription. The CovR/S reg-
ulatory system negatively regulates transcription of the hasABC
operon (15, 18, 19). To examine whether CovR also affects tran-
scription of HasS, we employed several approaches. First, we ex-
amined transcription of hasS and hasA in the 2221covR mutant
using qRT-PCR analysis. As expected, the 2221covR mutant has
a 16-fold increase in hasA transcript relative to that of the WT
strain, which is consistent with CovR being a negative regulator of
the capsule operon (Fig. 3A). We found that the HasS transcrip-
tion was about 16-fold higher in the 2221covR mutant than in
the WT strain (Fig. 3B). These results indicate that CovR also
represses the transcription of HasS.
Second, we constructed transcriptional fusions of the P2 pro-
moter with the luciferase (luc) reporter gene (Fig. 4A) and exam-
ined their activity in the WT and 2221covRmutant (Fig. 4B). The
results showed that the transcriptional activity of the P2 promoter
in the WT strain was 3 times higher than the activity obtained with
the vector alone. The activity of the P2::luc fusion was 3.5-fold
higher in the 2221covR strain than in the WT strain (Fig. 4B).
The reporter activity slightly peaked in the late exponential phase
and diminished rapidly during the stationary phase before largely
disappearing in the late stationary phase in both strain back-
grounds (see Fig. S3 in the supplemental material). Notably, a
P2T::luc fusion, which consists of the P2 promoter followed by
hasS and the terminator (Fig. 4A), produced the background level
of luciferase activity in the WT, indicating that the predicted ter-
minator terminates transcription under the conditions used in
FIG 2 The HasS region regulates HA capsule production in GAS. (A) Schematic representations of the construction of the mutants used in this study. Bent
arrows indicate the promoters in the hasA upstream region. The open triangles depict deletions that were constructed. The number of deleted nucleotides
is indicated inside the triangles. The relative position of each deletion from the HasS transcriptional start site (1) is shown. The terminator is shown as
a stem-loop. A bracket denotes changes in the sequence of the 10 box of the P1 promoter. (B) Capsule amounts measured in the 2221 parental isolate
and its mutants; (C) capsule amounts measured in the 2221covR strain and its mutants. The strains were harvested at the mid-exponential growth phase.
The experiments were performed in triplicate, and mean values SDs are shown. * denotes statistically significant differences relative to the WT control,
calculated using the Student test.
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this experiment. The same construct was active in the 2221covR
mutant (2-fold higher than the background level), suggesting that
read-through transcription occurred in the absence of CovR
(Fig. 4B). The luciferase assay data are consistent with CovR neg-
atively regulating HasS transcription.
Lastly, we studied CovR protein binding to the P2 promoter
region using an electrophoretic mobility shift assay (EMSA). We
found that CovR binds to a 270-bp DNA region which carries the
P2 promoter, and binding is dependent upon the concentration of
CovR (Fig. 5A). As seen in Fig. 5A, the binding was lost when
CovR was preincubated with the specific competitor. Further-
more, the binding was specific, since CovR failed to bind a 160-bp
DNA fragment amplified from an unrelated mga promoter region
(Fig. 5B). Similar to the hasS genomic locus, the mga promoter
region is also AT rich.
As it has been suggested by Federle and Scott (19), CovR binds
to the ATTARA consensus sequence. Examination of the P2 pro-
moter region shows two putative consensus CovR-binding se-
quences. The first site is located 17 bp upstream of the extended
10 box of P2, and the second site is present in the HasS termi-
nator (Fig. 1A). To investigate whether the HasS terminator re-
gion contains CovR-binding sequences, we introduced a deletion
(42T) in the P2 promoter DNA fragment. As seen in Fig. 5C,
binding of CovR to this probe requires a higher concentration of
the protein relative to binding to the WT probe, suggesting that
the affinity of CovR for the WT probe is higher. This observation
implies that the terminator has the CovR-binding sequences.
Taken together, our data indicate that CovR binds the P2 pro-
moter and represses HasS transcription.
Detection of read-through transcription from HasS into
hasA. We analyzed whether there could be read-through from the
P2 promoter into the downstream hasA gene. This was tested us-
ing RT-PCR using a reverse primer (primer R in Fig. 6A) embed-
ded within hasA and a series of four forward primers located at
increasing distances from the hasA promoter (primers F1, F2, F3,
and F4 in Fig. 6A), where F1 is located downstream of the P1
promoter, F2 is located between the P2 and P1 promoters, and F3
and F4 are located upstream of the P2 promoter. Surprisingly,
PCR products of the expected sizes were obtained for all four
PCRs using cDNA synthesized from MGAS2221 RNA as the tem-
plate (Fig. 6B). No PCR products were observed in reactions that
used template generated from control reactions with no reverse
transcriptase (RT). Thus, the data indicate that (i) there is an
additional promoter upstream of the P2 and (ii) at least some of
the HasS transcripts are being cotranscribed with hasA.
The results of analysis of transcriptional reporters prompted us
to test whether CovR effects the read-through transcription. We
determined transcription of the read-through region in the WT
strain and the 2221covR mutant using qRT-PCR analysis. The
2221covR mutant has a 5-fold increase in read-through tran-
script relative to the WT strain (Fig. 6C). This result is in agree-
ment with the enhanced activity of the P2 promoter in this mu-
tant.
Next, we investigated whether elevated capsule production in
the 2221P2hasS, 222142T, and 222163T strains is due to
increased read-through transcription to the downstream hasA or
rather results from deletion of CovR-binding sequences present in
FIG 3 qRT-PCR analysis of hasA and hasS mRNA transcripts. Graph showing
the mean values of fold change for hasA (A) and hasS (B) mRNA levels in the
mutants relative to those of MGAS2221. Both WT and mutant values were
relative to those of the internal control gene plr, with mutant values represent-
ing the fold change relative to that of WT, which was converted to 1. The
experiments were performed in triplicate, and mean values SDs are shown.
NE denotes the lack of transcript, as the reverse primer for qRT-PCR is in the
deleted region. * indicates statistically significant differences relative to WT
(P 0.05, unpaired t test).
FIG 4 Transcriptional analysis of the P2 promoter. (A) The schematic repre-
sentations of the transcriptional fusions to the luc reporter. The fusion names,
the fragment from the hasA upstream sequence that is carried by each plasmid
(thin line), the promoters (bent arrows), hasS (light-gray arrow), and the luc
gene (dark-gray arrow) are shown. Numbers indicate nucleotide positions
relative to the HasS transcriptional start (1). (B) Relative promoter activity
determined by luciferase assay at mid-exponential growth phase for P2::luc
and P2T::luc reporter plasmids in the WT and 2221covR strains. Luciferase
activity expressed by each strain was determined as described in Materials and
Methods. Each data point represents the average, and the error bars denote the
standard deviations derived from at least 3 experiments from independent
clones done in triplicate.
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the terminator region. To test this hypothesis, we determined the
read-through transcription in the WT, 2221P2hasS, and
222163T strains (Fig. 6C). We found that the 222163T mutant
produced 2.5 times more read-through transcript than the WT,
which is consistent with a lack of the terminator in this mutant. In
contrast, 2221P2hasS produced 2 times less read-through
transcript than the WT, indicating that the deletion of the P2
promoter decreases read-through transcription. Detection of
read-through transcription in the 2221P2hasS mutant further
confirms the presence of an additional promoter upstream of the
P2 promoter. Our data also indicate that the phenotype of this
mutant is not due to a positive effect of terminator deletion on the
read-through transcription. The results suggest that the deleted
region has regulatory elements, CovR-binding sequences, that
contribute to capsule transcription.
The P1 promoter is not active in strainMGAS2221. To inves-
tigate the contribution of the P1 promoter to transcription of the
hasABC operon, we constructed two mutants. In the MGAS2221
parental isolate and the 2221covR mutant, we mutated the10
box of the P1 promoter, creating the 2221P1 and 2221covRP1
mutants (Fig. 2A). The mutation changes the10 sequence from
TAGAAT to TCTAGA. As we demonstrated above, this mutation
completely abrogates transcription from the P1 promoter (see Fig.
S1B in the supplemental material). Remarkably, we found that the
2221P1 mutant had no significant defect in capsule production
(Fig. 2B), and the 2221covRP1 mutant showed a significant
decrease in capsule expression, producing 10 times less capsule
than the 2221covR mutant (Fig. 2C). This result indicates that in
the MGAS2221 strain, the P1 promoter is not active, probably due
to negative regulation of the CovR/S system, and the genes in the
operon are transcribed from P2 and the additional putative pro-
moter upstream of P2. Moreover, comparison of capsule levels
produced by the mutants revealed that the 2221covRP1mutant
expressed 2 times more capsule than the 2221P1mutant (see Fig.
S4 in the supplemental material), which is in agreement with in-
creased transcription from the P2 promoter in the absence of
CovR.
Capsule expression is controlled by the putative promoter
upstream of the P2 promoter in MGAS2221. To examine the
contribution of the P2 promoter to transcription of the hasABC
operon, we deleted the P2 promoter in two strain backgrounds,
2221P1 and 2221covRP1, creating the 2221P2P1 and
2221covRP2P1 mutants (Fig. 2A). Surprisingly, we found
that both mutants had a slight increase (1.7-fold) in capsule ex-
pression relative to that of the 2221P1 and 2221covRP1
strains (Fig. 2B and C; see also Fig. S4 in the supplemental mate-
rial), indicating a minor role of the P2 promoter in the hasABC
operon expression. Together, our data suggest that the putative
promoter upstream of P2 controls capsule expression in the
MGAS2221 strain. The increase in capsule expression in both mu-
tants might indicate that the RNA product from the HasS region
represses capsule expression.
To further investigate the role of the terminator in blocking
transcription from the upstream promoters, we deleted the
terminator in the 2221covRP1 strain, creating the 2221
covR42TP1 mutant (Fig. 2A). The 2221covRP1 strain
FIG 5 CovR binds specifically to the P2 promoter region. Gel mobility shift assay of increasing concentration of CovR binding to labeled DNA fragments (1.4
M) from P2 (A), mga (B), and P242T (C) promoter regions. (A) The gel mobility shift assay was carried out in the presence () or absence (–) of specific
competitor (85M P2 promoter DNA fragment) or nonspecific competitor (100Mmga promoter DNA fragment). Lanes 1 and 5, probe alone; lanes 2 to 4 and
9, 1.6M CovR; lane 6, 0.4M CovR; lane 7, 0.8M CovR; lane 8, 1.2M CovR; lane 10, 3.2M CovR; lane 11, 4.8M CovR; lane 12, 6.4M CovR; lane 13,
9.6 M CovR; lane 14, 12.8 M CovR; lane 15, 16 M CovR. (B) Lane 1, probe alone; lane 2, 9.6 M CovR; lane 3, 12.8 M CovR; lane 4, 16 M. (C) Lane 1,
probe alone; lane 2, 0.4 M CovR; lane 3, 0.8 M CovR; lane 4, 1.2 M CovR; lane 5, 1.6 M CovR; lane 6, 3.2 M CovR; lane 7, 4.8 M CovR; lane 8, 6.4 M
CovR; lane 9, 9.6 M CovR; lane 10, 12.8 M CovR; lane 11, 16 M CovR.
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was selected for mutagenesis, because in this genetic back-
ground, the terminator function in regulation of capsule
operon transcription is not masked by repressive activity of
CovR and transcription from the active P1 promoter. We ob-
served a slight increase (1.5-fold) in capsule expression relative
to that of the parent strain (Fig. 2B; see also Fig. S4 in the
supplemental material). Thus, our data indicate that in the
MGAS2221 strain, the terminator is not effective in vivo.
Genetic diversity in the HasS region. Recent whole-genome
analysis of GAS (10) reported that serotypes of M4 and M22
strains, including two M4 serotype genomes available in the
NCBI database, MGAS10750 and GA40634 (accession num-
bers CP000262.1 and AURU01000008, respectively), lack a
3,980-bp fragment carrying the hasABC operon. The alignment
of the DNA regions flanking the 3,980-bp locus indicates that
the genomic arrangements of two reference M4-serotype
strains are similar to those of four sequenced genomes of
Streptococcus dysgalactiae subsp. equisimilis (accession numbers
HE858529.1, CP002215.1, AP010935.1, and AP011114.1), the
closest known genetic relatives of GAS. Interestingly, the flanking
regions of M4 serotype strains are more homologous to GAS ge-
nomes, with an average identity of 99% for upstream and down-
stream flanks, than to S. dysgalactiae genomes, with average iden-
tities of 79% and 97% (see Fig. S5 in the supplemental material).
These observations suggest that a 3,980-bp fragment carrying hasS
and the hasABC operon has been acquired by GAS during its sep-
arate evolution and has become widely distributed among the
strains.
Sequence analysis of the hasA upstream region in 44 GAS ge-
nomes available in the NCBI database revealed a high level of
polymorphism in the hasS sequence (see Table S4 in the supple-
mental material). We found that 12 GAS strains display a nucleo-
tide change in a TG motif of the extended10 sequence of the P2
promoter (Fig. 7A). The mutation changes TTTGCTAAAAT to
TTTACTAAAAT and might result in the differential expression of
HasS between strains. Furthermore, we observed that the stem-
FIG 6 RT-PCR and qRT-PCR analyses of the hasA upstream region. (A) Schematic representation of the hasA upstream region. Shown is the approximate
location of the promoters (bent arrows). Horizontal arrows indicate the positions of the primers used for RT-PCR. (B) RT-PCR confirming the
transcription of the hasA upstream region. MGAS2221 gDNA and cDNA from reaction mixtures containing (RT) or not containing (RT) reverse
transcriptase were used as the templates in four PCRs. The relative locations of the primers used (numbered R, F1, F2, F3, and F4) are shown in panel A.
The samples without reverse transcriptase served as a control against gDNA contamination. (C) qRT-PCR analysis of the read-through transcription.
Graph showing the mean values of fold change for the read-through mRNA levels in the mutants relative to those of MGAS2221. Both WT and mutant
values were relative to those of the internal control gene, plr, with mutant values representing the fold change relative to that of WT, which was converted
to 1. The experiments were performed in triplicate, and mean values SDs are shown. * indicates statistically significant differences relative to WT (P
0.05, unpaired t test).
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FIG 7 Genetic diversity in the terminator region correlates with HA capsule expression. (A) Sequence alignment of the hasS region from serotypes M1, M2, M3,
M18, M49, and M53. The extended 10 promoter region is marked with a horizontal line. The terminator hairpin is highlighted by a bracket. Vertical arrow
denotes the HasS transcriptional start site. Gray boxes indicate nucleotide changes in the promoter and terminator sequence regions. (B) The secondary
structures of HasS from serotype M1, M49, and M53 were predicted using mfold analysis (43). (C) Production of HA capsule by different GAS serotypes. Capsule
amount measured in the strains harvested at the mid-exponential growth phase. The experiments were performed in triplicate, and mean values  SDs are
shown.
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loop structure of the HasS intrinsic terminator is 34 bp long in 20
GAS genomes (M12, M24, M28, M49, M59, and M66 serotypes)
(Fig. 7A and B; see also Table S4 in the supplemental material).
Seven GAS strains (M6, M53, and M41.2 serotypes) have an SNP
which would result in a more stable terminator stem-loop of 42 bp
long (Fig. 7A and B; see also Table S4 in the supplemental mate-
rial). In all M1 serotype strains, the stem-loop is 25 bp long due to
a deletion of 9 nt (Fig. 7A and B). Remarkably, in 10 strains (M2,
M3, M5, M12, M14, and M18 serotypes), the stem-loop is com-
pletely deleted (Fig. 7A; see also Table S4 in the supplemental
material). Four strains (M5 and M6 serotypes) contain an IS1239
insertion element located immediately downstream of the HasS
terminator sequence and upstream of the P1 promoter (see Table
S4 in the supplemental material). Finally, in three M6 serotype
strains, the hasS sequence contains three 29-nt tandem repeats
(see Fig. S6 in the supplemental material).
Genetic diversity in the terminator region correlates with
capsule expression. It has been previously reported that M3
serotype strains produce greater capsule levels than M1 isolates
(25) and M18 serotype strains display highly encapsulated phe-
notypes (50, 51). To assess whether genetic variability found in
the terminator region correlates with capsule expression, we
compared HA capsule levels in the GAS isolates harboring de-
leted terminator (M3, M5, and M18 isolates), with the GAS
strains harboring the weak terminator (M1 strain) and the
strong terminator (M49 and M53 strains). Only strains carry-
ing WT covRS were analyzed to rule out a confounding influ-
ence from the transcriptional regulator on the data. We found
that M3, M5, and M18 isolates produced greater capsule con-
centration than M1, M49, and M53 strains (Fig. 7C). In con-
trast, capsule expression in M49 and M53 strains was lower
than in the M1 strain (Fig. 7C). Hence, the differences in cap-
sule concentration produced by GAS might be associated with
sequence variation in the HasS terminator region.
Deletion of the HasS terminator affects virulence of GAS.
Since the HasS genomic regions from different GAS strains show
variability in the terminator sequence, we analyzed the impor-
tance of this region for virulence. The experiments were con-
ducted with the SF370 strain, which displays relatively low viru-
lence in mice and is also an M1 serotype (52). Similar to the
222163T strain, the SF37063T mutant produced 4-fold in-
creases in capsule expression relative to that of the SF370 strain.
We used GAS intraperitoneal injections to compare dissemina-
tion of the mutant in kidney, heart, and peritoneum with that of
the SF370 strain in a mouse model of invasive infection (53). Ten
hours after inoculation, the mutant-infected mice showed a sig-
nificantly higher bacterial count than the SF370 strain-infected
mice in all analyzed organs (Fig. 8).
In order to better understand the mechanism behind enhanced
virulence of the mutant, we compared the mutant and the SF370
strain growth in human blood. We found that the deletion of the
terminator does not affect bacterial growth in THY broth (Fig.
9A). In contrast, the mutant grew more rapidly in human blood
than the SF370 strain (Fig. 9B). To determine whether the fast
growth of the mutant in blood was due to less efficient killing of
the mutant by PMNs, we analyzed survival of the SF370 strain and
the mutant in a human neutrophil bactericidal assay. We discov-
ered that deletion of the terminator sequence makes the bacteria
significantly more resistant to neutrophil killing (Fig. 9C). In sum-
mary, our experiments demonstrate that the HasS terminator re-
gion negatively regulates GAS virulence.
DISCUSSION
Invasive bacterial infections represent an important public health
problem, because they are associated with high morbidity and
mortality in humans. It is widely accepted that most GAS strains
causing invasive infections arise from pharyngeal and other super-
ficial infections (54). Invasive GAS infections are often associated
with spontaneous mutations in the genes encoding the CovR/S
system, resulting in massive HA capsule production and hyper-
virulence of GAS (7, 22, 55). Although GAS requires the capsule
for protection against the host immune response during infection,
capsule biosynthesis also represents a great metabolic burden on
the cell, potentially slowing cell growth and division. Thus, cap-
sule expression requires effective and sensitive control mecha-
nisms to avoid excessive capsule overproduction. In this work, we
analyzed the upstream region of the capsule operon promoter and
identified and characterized a transcriptionally active region com-
prised of a novel noncoding sRNA, HasS. HasS is present in all
available genomes of GAS except the M4 serotype, which does not
have the hasABC operon also. Although other streptococcal spe-
cies like Streptococcus equi, Streptococcus uberis, Streptococcus
parauberis, and Streptococcus iniae harbor the capsule biosynthesis
operon, they lack HasS, indicating that this sRNA is GAS specific.
Recent studies employing computation prediction methods
and intergenic tiling array approaches discovered multiple candi-
FIG 8 Viable bacteria recovered from organs of BALB/c mice at 10 h postinfection. Organs from which bacteria were recovered include the peritoneum (A),
kidney (B), and heart (C). Mice were infected intravenously with either the WT (strain SF370) or the SF37063T mutant. Black circles represent WT-infected
mice (n 8), and gray boxes represent SF37063T mutant-infected mice (n 8). The horizontal bar is the mean of the eight mice per treatment group; error
bars represent standard errors of the means. P values were determined using an unpaired t test: P 0.0006 for peritoneum, P 0.027 for kidney, and P 0.014
for heart.
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date sRNAs in the GAS genome (56–58). However, HasS was
missed from these studies, probably due to its low expression in
the bacteria. This implies that more sensitive methods of genome-
wide analysis are required for a comprehensive identification of
sRNAs in GAS. While the numerous sRNAs were predicted in
GAS genomes, only some of them were experimentally validated,
and a very limited number were functionally studied. The best-
characterized GAS sRNA is FasX, which is involved in the regula-
tion of two important virulence factors, the collagen-binding pilus
(59) and streptokinase (60, 61). The regulation of key virulence
factors by FasX demonstrates that sRNAs play a prominent role in
GAS pathogenesis.
Previously, it has been shown that CovR represses hasABC
transcription by binding to an extending region comprising five
AT-rich sequences located upstream and downstream of the P1
promoter (19). The close location of hasS to hasA in the majority
of GAS strains suggests that they might share the same regulatory
region, which coordinates their expression in response to environ-
mental signals. Federle and Scott (19) did not search for CovR-
binding sites in the HasS genomic region, possibly due to the fact
that they used the type M6 GAS strain JRS4, which contains the
IS1239 transposase inserted between hasS and the P1 promoter.
We demonstrated that HasS transcription initiated from the P2
promoter is also negatively regulated by CovR. The gel shift assay
using the DNA fragment from the HasS genomic region indicates
the presence of CovR-binding sequences within the terminator
region of HasS. These findings show that CovR regulation of the
P2 promoter is direct.
We found that in the absence of the P1 promoter, the
MGAS2221 strain produces the normal level of capsule, indi-
cating that this promoter is fully repressed by CovR and does
not contribute to capsule operon transcription, under the con-
ditions tested. This finding is in line with our observation that
the HasS terminator does not work efficiently, allowing read-
through transcription into hasA. Furthermore, our RT-PCR
experiments and analyses of read-through transcription in the P2
deletion mutant and capsule production by the mutants with inactive
P1 and P2 promoters indicate that there is another promoter up-
stream of the P2 promoter. In the MGAS2221 strain, this putative
promoter controls the hasA transcription, allowing the pathogen to
maintain a low basal level of capsule in the presence of active CovR.
Consistent with this notion, deletion of the terminator in the
MGAS2221 strain leads to release of CovR repression, enhanced
read-through, and hasABC transcription and capsule production.
Intriguingly, deletion of the P2 promoter also has a positive
effect on capsule expression, suggesting that the RNA product
from this region, HasS may negatively control capsule expres-
sion. It is possible that HasS acts as a trans-acting regulatory
sRNA by base pairing with the hasA transcript, leading to its
degradation. Another hypothesis is that HasS may regulate
capsule expression indirectly by affecting other targets. It has
been recently reported that the insertion of a transposon at 9 nt
upstream of the P2 10 promoter element resulted in the in-
creased capsule production at 37°C in the CovR deletion mu-
tant of GAS HSC5 (M14 serotype) (62). This report further
suggests activity of the HasS region at the RNA level. As the
HasS region contains CovR-binding sites, the phenotype of our
P2 promoter deletion mutants could also be a result of elevated
P1 promoter activity caused by decreased binding of CovR to
this DNA locus. Thus, the regulatory region of the capsule
operon is much more complex than previously envisioned, and
it remains to be determined what the exact roles of CovR, HasS,
FIG 9 Deletion of the HasS terminator affects growth of bacteria in human blood and phagocytosis by PMNs. (A) Growth of the WT (strain SF370) and
the SF37063T mutant in THY broth; (B) growth of the WT (strain SF370) and the SF37063T mutant in human blood; (C) percentage of GAS survival
following 0, 30, 60, and 180 min of incubation with PMNs relative to untreated bacteria incubated with HBSS. The percent survival was calculated using
the formula (CFUn/CFU0) 	 100, where CFU0 is the number of viable bacteria incubated with HBSS and CFUn is the number of surviving bacteria after
incubation with PMNs. The experiments with whole blood/PMNs from three separate blood donors were performed. Panels A, B, and C show the results
of one representative donor (means  SDs of triple measurements from two independently growing clones).
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the terminator, and the additional promoter upstream of P2
are in the regulation of capsule biosynthesis.
Current evidence is in favor of a hypothesis that GAS inva-
sive strains arise during minor skin or throat infections as a
result of the accumulation of spontaneous mutations in critical
regulatory regions. A striking and unexpected feature of this
novel regulatory region is a remarkable variability among GAS
clinical isolates. Our analysis of the sequences of GAS strains
of different serotypes identified single nucleotide polymor-
phisms, deletions, and insertions clustered in the HasS region.
These polymorphisms are likely to affect the expression and
biological function of HasS. Notably, a high degree of diver-
gence was detected in the terminator region, suggesting that
this regulatory element is under strong selective pressure in
GAS. The terminator sequence is found frequently weakened
by mutations/deletions or completely deleted. Moreover,
among six analyzed M12 serotype strains, four strains have lost
the terminator, suggesting that this deletion is a recent evolu-
tionarily event. In this study, we compared virulence of the
serotype M1 SF370 strain with that of the mutant lacking the
terminator. We observed that the mutant has increased growth
in human blood, is highly resistant to neutrophil killing, and is
considerably more virulent in the mouse model of GAS inva-
sive disease than the WT strain. Thus, our data indicate that
this regulatory region significantly contributes to GAS viru-
lence.
The observed genetic diversity in the HasS region might in part
explain the wide phenotypic variation in encapsulation and viru-
lence among GAS clinical isolates. Our data and published obser-
vations (25) suggest that deletion of the terminator sequences cor-
relates with enhanced capsule expression in GAS isolates. Thus,
our results suggest that naturally occurring mutations in the ter-
minator region enhance GAS virulence and predispose the patho-
gen to switch from superficial to invasive infection.
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